AKT is a therapeutic target in myeloproliferative neoplasms

The majority of patients with BCR-ABL1-negative myeloproliferative neoplasms (MPN) harbor mutations in JAK2 or MPL, which lead to constitutive activation of the JAK/STAT, PI3K, and ERK signaling pathways. JAK inhibitors by themselves are inadequate in producing selective clonal suppression in MPN an...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Khan, Irum, Huang, Zan, Wen, Qiang, Stankiewicz, Monika J., Gilles, Laure, Goldenson, Benjamin, Schultz, Rachael, Diebold, Lauren, Gurbuxani, Sandeep, Finke, Christy M., Lasho, Terra L., Koppikar, Priya, Pardanani, Animesh, Stein, Brady, Altman, Jessica K., Levine, Ross L., Tefferi, Ayalew, Crispino, John D.
Formato: Artigo
Idioma:Inglês
Publicado em: 2013
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4023863/
https://ncbi.nlm.nih.gov/pubmed/23748344
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/leu.2013.167
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados